苯达莫司汀治疗多发性骨髓瘤研究进展  

Progress of bendamustine in treatment of multiple myeloma

作　　者：朱贵华[1] 庄万传[1] Zhu Guihua;Zhuang Wanchuan(Department of Hematology,the Second People's Hospital of Lianyungang,Lianyungang 222000,China)

机构地区：[1]连云港市第二人民医院血液内科,连云港222000

出　　处：《白血病．淋巴瘤》2022年第12期766-768,共3页Journal of Leukemia & Lymphoma

基　　金：连云港市卫生科技项目(201822,202019)。

摘　　要：苯达莫司汀是氮芥的双功能衍生物,由于其特定的活性模式和可接受的毒性,以及对烷基化剂耐药患者的临床活性,成为治疗多发性骨髓瘤患者的一个选择。苯达莫司汀单药或联合蛋白酶体抑制剂、联合免疫调节剂在复发难治多发性骨髓瘤患者中均有广泛应用;苯达莫司汀在多发性骨髓瘤患者自体造血干细胞移植预处理中的应用,延长了无进展生存时间和总生存时间,增加了缓解深度。现就苯达莫司汀在多发性骨髓瘤治疗中的研究进展进行综述。Bendamustine,a bifunctional derivate of nitrogen mustard,is an attractive treatment option for multiple myeloma(MM)due to its specific mode of activity,favorable toxicity profile,and clinical activity in patients resistant to alkylating agent.Bendamustine single agent and its combination with immunomodulators or proteasome inhibitors have been widely used in the relapsed/refractory MM patients.Bendamustine has brought the longer progression-free survival,overall survival time and deeper remission in the autologous stem cell transplantation pre-conditioning for MM patients.This paper reviews the treatment progress of bendamustine for MM.

关 键 词：多发性骨髓瘤 抗肿瘤联合化疗方案 苯达莫司汀 

分 类 号：R733.3[医药卫生—肿瘤]